Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.

Abstract

BACKGROUND:

Clinical experience with the radiolabeled somatostatin analogues 90Y-DOTATOC and, more recently, 177Lu-DOTATATE, is ongoing since more than a decade in few centers. Dosimetric studies demonstrated that 90Y-DOTATOC and 177Lu-DOTATATE are able to deliver high doses to somatostatin receptor sst2-expressing tumors and low doses to normal organs.

RESULTS AND CONCLUSIONS:

Clinical studies demonstrated that partial and complete objective responses in up to 30% of patients can be obtained, with a great survival benefit in treated patients. Side effects may involve the kidney and the bone marrow and are usually mild. Renal protection is used to minimize the risk of a late decrease of renal function.

• Authors: L Bodei, G Pepe, G Paganelli
• Journal: European review for medical and pharmacological sciences (Eur Rev Med Pharmacol Sci) Vol. 14 Issue 4 Pg. 347-51 (Apr 2010) ISSN: 1128-3602 [Print] Italy
• PMID: 20496546 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents
• Radioisotopes
• Radiopharmaceuticals
• Receptors, Peptide
• Yttrium Radioisotopes
• Somatostatin
• Lutetium
• Octreotide
• Edotreotide

Topics

• Antineoplastic Agents (adverse effects, therapeutic use)
• Humans
• Lutetium (therapeutic use)
• Neuroendocrine Tumors (radiotherapy)
• Octreotide (analogs & derivatives, therapeutic use)
• Radioisotopes (adverse effects, therapeutic use)
• Radiopharmaceuticals (therapeutic use)
• Receptors, Peptide (drug effects)
• Somatostatin (adverse effects, analogs & derivatives, therapeutic use)
• Yttrium Radioisotopes (therapeutic use)